| Dear Friend:
We are pleased to provide you with an MMRC Update. This briefing was created to keep you informed of the MMRC's progress toward its ultimate goal of accelerating drug development and improving patient outcomes in multiple myeloma. We hope that you find this newsletter informative and we welcome any feedback you may have. For more information, contact us at info@themmrc.org |
The Multiple Myeloma Research Consortium (MMRC), in collaboration with Nereus Pharmaceuticals, Inc., is preparing to initiate in early 2007 a Phase 1 trial of NPI-0052 in patients with multiple myeloma. The MMRC Member Institutions expected to enroll patients in the trial are Dana-Farber Cancer Institute, Roswell Park Cancer Institute, Ohio State University, and the University of Chicago. Correlative science studies relevant to this trial will be performed in MMRC member institution laboratories. "The preclinical data show us that NPI-0052 is a potent and selective proteasome inhibitor with the potential to treat a variety of cancers, including multiple myeloma," said Matthew A. Spear, M.D., Chief Medical Officer of Nereus Pharmaceuticals, Inc. "We look forward to collaborating with the investigators at the MMRC's four prestigious cancer centers to expand the clinical trial program and evaluate the potential of this therapeutic drug candidate in multiple myeloma."
Keryx Biopharmaceuticals, Inc., in collaboration with
the MMRC, has initiated a Phase I clinical trial of
perifosine, Revlimid®, and dexamethasone for the
treatment of relapsed or refractory multiple myeloma.
This trial, the first oral triplet being studied in
the clinical setting for the treatment of myeloma, is
spearheaded by the University of Michigan (Ann Arbor,
Mich.), one of the MMRC's 13 world-renowned Member
Institutions, and will also enroll at three other MMRC
Member Institutions. Click here for more information.
The MMRC has several clinical trials under development
in collaboration with biotech and pharmaceutical
companies and looks forward to launching these trials
in the first and second quarters of 2007. The MMRC
project pipeline is currently comprised of several
novel compounds, including proteasome inhibitors, mTOR
inhibitors, an immunomodulatory compound, an HDAC
inhibitor, and a kinase inhibitor. If you are
interested in working with the MMRC, please contact
Kathy Giusti - giustik@themmrf.org or 203-652-0201 - or
Steven Young at youngs@themmrc.org or 203-652-0213.
